A Phase 3 interventional study of Entecavir and Placebo in Chronic Hepatitis B Virus, Pediatric, sponsored by Bristol-Myers Squibb. Completed at 44 sites in 14 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-05-09.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 19th largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2010, is one of 13 in phase 3, and was the 30th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2010, is one of 11 in phase 3, and was the 20th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection
Key Inclusion Criteria
Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
Drug: Entecavir
Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
Drug: Placebo
Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
Also known as: Baraclude, BMS-200475
Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48
Suppression=HBV DNA\<50 IU/mL (approximately 300 copies/mL) using the Roche COBAS TaqMan HBV Test for use with the High Pure System assay; seroconversion=undetectable HBeAg and detectable anti-hepatitis B e antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
Time frame: At Week 48
Percentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 48
While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
Time frame: At Week 48
Percentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 48
While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
Time frame: At Week 48
Percentage of Participants With Hepatitis B Virus DNA <Limit of Quantitation (LOQ) at Week 48
LOQ=29 IU/mL. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
Time frame: At Week 48
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 (Undetectable HBeAg and Presence of Anti-HBeAb)
Percentage of participants in the primary cohort with HBeAg seroconversion (undetectable HBeAg and presence of anti-HBe antibodies) at week 48
Time frame: At Week 48
Percentage of Participants Who Achieved Sustained HBeAg Seroconversion During Off-treatment Follow up Among Participants Who Achieved HBeAg Seroconversion at End of Dosing (EOD).
Participants who demonstrated HBeAg seroconversion at EOD were followed and assessed for presence of sustained HBeAg seroconversion during entire study. The study reached the end of dosing (EOD) on 22 Feb-2016.
Time frame: Week 48, EOD (2 years)
Number of Participants With Adverse Events (Including Palatability Issues), SAEs, Discontinuous Due to Adverse Events, and HBV Disease Progression Through Week 48
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.
Time frame: Day 1 through Week 48 on blinded therapy
Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4)
Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. INR=international normalization ratio of prothrombin time; ULN=upper limit of normal. Hemoglobin (g/dL): Grade 1=10-10.9; Grade 2=9-9.9; Grade 3=7-8.9; Grade 4= \<7. Platelets (/mm\^3): Grade 1=100,000-124,999; Grade 2=50,000-99,999; Grade 3=25,000-49,999; Grade 4= \<25,000. INR (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-2; Grade 3=2.1-3; Grade 4= \>3. WBC (/mm\^3): Grade 1=2000-2500; Grade 2=1500-1999; Grade 3=1000-1499; Grade 4= \<1000. Neutrophils (/mm\^3): Grade 1=1000-1300; Grade 2=750-999; Grade 3=500-749; Grade 4= \<500.
Time frame: Day 1 through Week 48 on blinded therapy
Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4) (Continued)
Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; ULN=upper limit of normal; LLN=lower limit of normal. ALT, AST (\*ULN): Grade 1=1.25-2; Grade 2=2.6-5; Grade 3=5.1-10; Grade 4 =\> 10. Bilirubin (\*ULN): Grade 1 = 1.1-1.5; Grade 2=1.6-2.5; Grade 3 = 2.6-5; Grade 4= \>5. Albumin (g/dL): Grade 1=3- \<LLN; Grade 2=2-2.9; Grade 3= \<2. Lipase (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-3; Grade 3=3.1-5; Grade 4= \>5. BUN/urea (\*ULN): Grade 1=1.25-\<2.6; Grade 2=2.6-\<5.1; Grade 3=5.1-10; Grade 4= \>10. Chloride, high (mEq/L): Grade 1=113-\<117; Grade 2=117-\<121; Grade 3=121-125; Grade 4= \>125. Potassium, low (mEq/L): Grade 1=3-3.4; Grade 2=2.5-\<3; Grade 3=2-\<2.5; Grade 4=\<2. Potassium, high (mEq/L): : Grade 1= 5.6-\<6.1; Grade 2=6.1-\<6.6; Grade 3=6.6-7; Grade 4= \>7. Sodium, high (mEq/L): Grade 1=146\<151; Grade 2=151-\<155; Grade 3=155-\<160; Grade 4= \>=160.
Time frame: Day 1 through Week 48 on blinded therapy
Percentage of Participants With HBeAg Seroconversion on ETV Over-time at Week 96 (All ETV Cohort)
HBe seroconversion=undetectable HBe antigen and detectable anti-HBe antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
Time frame: At Week 96
Percentage of Participants Who Maintained HBeAg Seroconversion at Week 96 (End of Blinded Therapy) Among Participants With HBeAg Seroconversion at Week 48
Participants who achieved HBeAg seroconversion by Week 48 and maintained seroconversion to week 96
Time frame: At Week 96
Percentage of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Related AEs, Grade 2-4 Related AEs, Grade 3-4 AEs, Malignancies, ALT Flares, and Hepatic Disease Progression Through Week 96
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.
Time frame: Day 1 through Week 96
Percentage of Participants With HBeAg Seroconversion (Undetectable HBeAg and Presence of Anti-HBeAb) up to Week 96
On Treatment through week 96 - 2 year cohort NC = F: (The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures.)
Time frame: up to week 96
Histological Analysis (Percentage) Among Participants With Available Liver Biopsy Data
Liver function test elevations and abnormalities on blinded and open-label ETV (the All ETV Safety Cohort). Participants who experienced elevation of alanine aminotransferase (ALT) greater than three times ETV (entecavir) baseline measure (Participants who displayed liver biopsy with ALT value greater than three times baseline.)
Time frame: Between weeks 48 and 96
Percentage of Participants With HbeAg Loss at Weeks 48 and 96
HBeAg Loss (NC = F and NC = M) - On Treatment through Week 96 - Year 2 Efficacy Cohort Non-Completer - Failure (NC=F): The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures. Non-Completer - Missing (NC=M): The numerator was based on participants meeting the response criteria. The denominator was based on participants with data at the analysis week. Participants who had missing data at the analysis week were excluded.
Time frame: At 48 and 96 weeks
| Milestone | Entecavir | Placebo |
|---|---|---|
| Started | 120 | 60 |
| Received treatment | 120 | 60 |
| Primary endpoint cohort | 82 | 41 |
| Completed | 113 | 53 |
| Not completed | 7 | 7 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Poor compliance or noncompliance | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Subject request to stop study treatment | 1 | 0 |
| Withdrew: Removal by medical monitor | 0 | 1 |
| Milestone | Entecavir | Placebo |
|---|---|---|
| Started | 111 | 58 |
| Completed | 92 | 43 |
| Not completed | 19 | 15 |
| Withdrew: Withdrawal by subject | 13 | 8 |
| Withdrew: Investigator left institution | 0 | 1 |
| Withdrew: Lost to follow-up | 6 | 6 |
Suppression=HBV DNA\<50 IU/mL (approximately 300 copies/mL) using the Roche COBAS TaqMan HBV Test for use with the High Pure System assay; seroconversion=undetectable HBeAg and detectable anti-hepatitis B e antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 | 24.4 | 2.4 |
While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| Percentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 48 | 46.3 | 2.4 |
While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| Percentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 48 | 67.1 | 22.0 |
LOQ=29 IU/mL. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| Percentage of Participants With Hepatitis B Virus DNA <Limit of Quantitation (LOQ) at Week 48 | 42.7 | 2.4 |
Percentage of participants in the primary cohort with HBeAg seroconversion (undetectable HBeAg and presence of anti-HBe antibodies) at week 48
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 (Undetectable HBeAg and Presence of Anti-HBeAb) | 24.4 | 12.2 |
Participants who demonstrated HBeAg seroconversion at EOD were followed and assessed for presence of sustained HBeAg seroconversion during entire study. The study reached the end of dosing (EOD) on 22 Feb-2016.
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| EOD (end of dosing) | 100.0 | 100.0 |
| Week 48 | 74.4 | 59.1 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.
| participants | Entecavir | Placebo |
|---|---|---|
| Deaths | 0 | 0 |
| Serious Adverse Events | 4 | 7 |
| Discontinuation due to Adverse Event | 0 | 2 |
| any adverse event | 78 | 46 |
| Related Adverse Events | 11 | 6 |
| Related Grade 2 - 4 Adverse Events | 4 | 2 |
| Grade 3 - 4 Adverse Events | 4 | 3 |
| ALT Flares | 2 | 5 |
| HBV disease progression | 0 | 0 |
| Malignant neoplasms or pre-malignant lesions | 0 | 0 |
Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. INR=international normalization ratio of prothrombin time; ULN=upper limit of normal. Hemoglobin (g/dL): Grade 1=10-10.9; Grade 2=9-9.9; Grade 3=7-8.9; Grade 4= \<7. Platelets (/mm\^3): Grade 1=100,000-124,999; Grade 2=50,000-99,999; Grade 3=25,000-49,999; Grade 4= \<25,000. INR (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-2; Grade 3=2.1-3; Grade 4= \>3. WBC (/mm\^3): Grade 1=2000-2500; Grade 2=1500-1999; Grade 3=1000-1499; Grade 4= \<1000. Neutrophils (/mm\^3): Grade 1=1000-1300; Grade 2=750-999; Grade 3=500-749; Grade 4= \<500.
| Participants | Entecavir | Placebo |
|---|---|---|
| Hemoglobin | 5 | 4 |
| Platelets | 3 | 2 |
| INR | 2 | 6 |
| White blood cells (WBC) | 2 | 1 |
| Neutrophils + bands (absolute) | 14 | 2 |
Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; ULN=upper limit of normal; LLN=lower limit of normal. ALT, AST (\*ULN): Grade 1=1.25-2; Grade 2=2.6-5; Grade 3=5.1-10; Grade 4 =\> 10. Bilirubin (\*ULN): Grade 1 = 1.1-1.5; Grade 2=1.6-2.5; Grade 3 = 2.6-5; Grade 4= \>5. Albumin (g/dL): Grade 1=3- \<LLN; Grade 2=2-2.9; Grade 3= \<2. Lipase (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-3; Grade 3=3.1-5; Grade 4= \>5. BUN/urea (\*ULN): Grade 1=1.25-\<2.6; Grade 2=2.6-\<5.1; Grade 3=5.1-10; Grade 4= \>10. Chloride, high (mEq/L): Grade 1=113-\<117; Grade 2=117-\<121; Grade 3=121-125; Grade 4= \>125. Potassium, low (mEq/L): Grade 1=3-3.4; Grade 2=2.5-\<3; Grade 3=2-\<2.5; Grade 4=\<2. Potassium, high (mEq/L): : Grade 1= 5.6-\<6.1; Grade 2=6.1-\<6.6; Grade 3=6.6-7; Grade 4= \>7. Sodium, high (mEq/L): Grade 1=146\<151; Grade 2=151-\<155; Grade 3=155-\<160; Grade 4= \>=160.
| participants | Entecavir | Placebo |
|---|---|---|
| ALT | 113 | 59 |
| AST | 87 | 51 |
| Total bilirubin | 5 | 6 |
| Albumin | 0 | 1 |
| Lipase | 38 | 20 |
| BUN/Urea | 10 | 2 |
| Chloride, high | 2 | 1 |
| Potassium, low | 1 | 1 |
| Potassium, high | 1 | 0 |
| Sodium, high | 8 | 4 |
HBe seroconversion=undetectable HBe antigen and detectable anti-HBe antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.
| Percentage of participants | Blinded and Open-Label (All ETV) |
|---|---|
| Percentage of Participants With HBeAg Seroconversion on ETV Over-time at Week 96 (All ETV Cohort) | 38.6 |
Participants who achieved HBeAg seroconversion by Week 48 and maintained seroconversion to week 96
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| Week 48 | 24.2 | 10.0 |
| Week 96 | 36.7 | 20.0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.
| Percentage of participants | Blinded and Open-Label (All ETV) |
|---|---|
| Deaths | 0 |
| SAEs | 4.7 |
| Discontinuations due to AEs | 0.6 |
| Related AEs | 8.2 |
| Grade 2-4 Related AEs | 2.3 |
| Grade 3-4 AEs | 4.1 |
| Malignancies | 0 |
| ALT flares | 1.8 |
| Hepatic disease progression | 0 |
On Treatment through week 96 - 2 year cohort NC = F: (The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures.)
| Percentage of participants | Entecavir |
|---|---|
| Percentage of Participants With HBeAg Seroconversion (Undetectable HBeAg and Presence of Anti-HBeAb) up to Week 96 | 40.8 |
Liver function test elevations and abnormalities on blinded and open-label ETV (the All ETV Safety Cohort). Participants who experienced elevation of alanine aminotransferase (ALT) greater than three times ETV (entecavir) baseline measure (Participants who displayed liver biopsy with ALT value greater than three times baseline.)
| Percentage of participants | Blinded and Open-Label (All ETV) |
|---|---|
| Histological Analysis (Percentage) Among Participants With Available Liver Biopsy Data | 5.9 |
HBeAg Loss (NC = F and NC = M) - On Treatment through Week 96 - Year 2 Efficacy Cohort Non-Completer - Failure (NC=F): The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures. Non-Completer - Missing (NC=M): The numerator was based on participants meeting the response criteria. The denominator was based on participants with data at the analysis week. Participants who had missing data at the analysis week were excluded.
| Percentage of participants | Entecavir | Placebo |
|---|---|---|
| 48 weeks | 25.0 | 10.0 |
| 96 Weeks | 40.8 | — |
Collected over All non-serious adverse events were collected from start of study treatment through Week 48, while all serious adverse events were evaluated through out the study (5 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETV (Entecavir) | 0/120 (0%) | 4/120 (3.3%) | 76/120 (63.3%) |
| PLACEBO | 0/60 (0%) | 9/60 (15%) | 45/60 (75%) |
| Event | ETV (Entecavir) | PLACEBO |
|---|---|---|
| Hepatic function abnormalHepatobiliary disorders | 0/120 | 2/60 |
| GastritisGastrointestinal disorders | 0/120 | 1/60 |
| Inflammatory bowel diseaseGastrointestinal disorders | 0/120 | 1/60 |
| CellulitisInfections and infestations | 0/120 | 1/60 |
| Chronic hepatitis bInfections and infestations | 0/120 | 1/60 |
| Infectious colitisInfections and infestations | 0/120 | 1/60 |
| MastoiditisInfections and infestations | 0/120 | 1/60 |
| PharyngitisInfections and infestations | 0/120 | 1/60 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/120 | 1/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/120 | 1/60 |
| Event | ETV (Entecavir) | PLACEBO |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/120 | 14/60 |
| Upper respiratory tract infectionInfections and infestations | 19/120 | 12/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/120 | 12/60 |
| PharyngitisInfections and infestations | 5/120 | 11/60 |
| VomitingGastrointestinal disorders | 14/120 | 10/60 |
| PyrexiaGeneral disorders | 18/120 | 10/60 |
| Abdominal painGastrointestinal disorders | 9/120 | 9/60 |
| HeadacheNervous system disorders | 18/120 | 9/60 |
| DiarrhoeaGastrointestinal disorders | 7/120 | 7/60 |
| BronchitisInfections and infestations | 8/120 | 6/60 |
All participants who received study drug
| Age, Continuous(Years) | Entecavir | Placebo | Total |
|---|---|---|---|
| Mean | 10.5 ± 4.87 | 10.8 ± 4.82 | 10.6 ± 4.84 |
| Age, Customized(participants) | Entecavir | Placebo | Total |
|---|---|---|---|
| >=2 years to <=6 years | 27 | 14 | 41 |
| >6 years to <=12 years | 31 | 15 | 46 |
| >12 years to <18 years | 62 | 31 | 93 |
| Sex: Female, Male(Participants) | Entecavir | Placebo | Total |
|---|---|---|---|
| Female | 42 | 29 | 71 |
| Male | 78 | 31 | 109 |
| Ethnicity (NIH/OMB)(Participants) | Entecavir | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 48 | 21 | 69 |
| Unknown or Not Reported | 70 | 39 | 109 |
| Race/Ethnicity, Customized(participants) | Entecavir | Placebo | Total |
|---|---|---|---|
| Asian | 57 | 30 | 87 |
| Black/African American | 14 | 2 | 16 |
| Native Hawaiian/Other Pacific Islander | 1 | 0 | 1 |
| White | 44 | 27 | 71 |
| Other | 4 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2010 to primary completion in Mar 2013, 33 months.
Results were first posted in Apr 2014, 1 year after primary completion.
Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 33 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir